BioSpace News Archive

This lipid-based system is able to tightly target antigen-presenting cells and thus trigger a rapid, persistent and robust T cell response against various cancers.

Orphazyme A/S, a late-stage biopharmaceutical company, provides an update on the regulatory status in the United States of its investigational product arimoclomol for Niemann-Pick disease type C following a recently held Type A meeting with the U.S. Food and Drug Administration.

Merck, known as MSD outside the United States and Canada, announced new data from studies evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, at the Society for Melanoma Research 2021 Congress.

Antengene Corporation Limited announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for ATG-101, a bi-specific monoclonal antibody in development as a potential treatment for metastatic/advanced solid tumors and B-cell non-Hodgkin’s lymphoma.

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS are pleased to announce the creation of Dania Therapeutics ApS to discover small molecules inhibitors against new undisclosed oncology targets.

Survey data released show that only 36% of people know that lung cancer screening is available and 29% know that lung cancer is the leading cancer killer of woman and men.

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced the pricing of its initial public offering of 20,312,500 American depositary shares at a public offering price of $16.00 per ADS, for gross proceeds of approximately $325.0 million, before deducting underwriting discounts and commissions and offering expenses.

Moderna, Inc. provided an update that the U.S. Food and Drug Administration has notified the Company that it will require additional time to complete its assessment of Moderna’s Emergency Use Authorization request for the use of the Moderna COVID-19 vaccine at the 100 µg dose level in adolescents 12 to 17 years of age.

Everest Medicines announced that it has repurchased 1,095,000 ordinary shares equivalent to approximately HK$50 million in the open market in the period from October 4, 2021 to October 29, 2021, at an average price of HK$45.63 per share.

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc., announces the Investigational New Drug application approval by U.S. Food and Drug Administration and initiation of global development of ASC43F, a first-in-class, fixed-dose combination with dual targets of thyroid hormone receptor beta and farnesoid X receptor for the treatment of non-alcoholic steatohepatitis.